Expression of MHC products and leucocyte differentiation antigens in gynaecological neoplasms: an immunohistological analysis of the tumour cells and infiltrating leucocytes.
Monoclonal antibodies directed against monomorphic determinants of Class I and Class II products of the major histocompatibility complex (MHC) and against leucocyte differentiation antigens were used in an indirect immunoperoxidase technique to compare their expression in normal and malignant disease of the ovary, cervix and endometrium. MHC Class I products, strongly expressed on normal ovarian epithelium, were uniformly absent from 7/8 ovarian carcinomas of varying histology. Lack of Class I expression was also a feature of 6/10 cervical carcinomas and of 4/8 endometrial carcinomas, in comparison with their respective normal tissues. Relative to normal tissue epithelium MHC Class II products, could be either lost or gained, the pattern of expression being either uniform or heterogeneous. Leucocytes were sparse in normal ovary but more numerous in cervix and endometrium. In tumours, with few exceptions, they were abundant, though usually confined to the stroma. T cells, largely of cytotoxic/suppressor (OKT8) phenotype, tended to predominate though in some tumours, particularly cervical carcinoma, large numbers of macrophages and to a lesser extent, B cells were sometimes detected. By contrast, leucocytes of natural killer (NK) phenotype were virtually non-existent in any tumour or normal tissue. The ingress of leucocytes into gynaecological neoplasms does not appear to be a random event and may be evoked by an immune response against tumour-associated antigens. However, the relationship between in situ mononuclear cell infiltration and MHC expression on epithelial tumour cells is complex and remains to be elucidated.
A
A
Ferguson
M
M
Moore
H
H
Fox
D000230:Adenocarcinoma / Q000276:immunology; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology*; D002584:Cervix Uteri / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D000939:Epitopes / Q000276:immunology; D005260:Female; D005833:Genital Neoplasms, Female / Q000276:immunology*; D006801:Humans; D007962:Leukocytes / Q000276:immunology*; D008285:Major Histocompatibility Complex; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology; D010053:Ovary / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000473:pathology; D014594:Uterine Neoplasms / Q000276:immunology / Q000473:pathology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D000939:Epitopes